BiotechTube
Biopharma Group

Biopharma Group

Cambridge, United Kingdom· Est.
biopharmagroupcdmo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Biopharma Group is a specialized CDMO and consultancy focused on lyophilization technology, serving clients globally from its base in Cambridge, UK. The company offers end-to-end services including contract R&D, analytical testing, clinical-scale manufacturing (with a GMP suite coming online), and proprietary lyobead processing solutions. With ISO 9001 and ISO 13485 accreditations, over 5,000 projects completed, and a strong training division, it positions itself as a knowledge hub and strategic partner for complex drying processes. Its business model is entirely service-based, catering to a diverse clientele from startups to large pharmaceutical companies.

Drug DeliveryCDMOBiologics

Technology Platform

Integrated lyophilization (freeze-drying) expertise encompassing formulation science, cycle development, analytical testing, specialized cytotoxic/HPAPI handling, and proprietary lyobead processing technology. It is a process and service platform, not a therapeutic discovery platform.

Opportunities

The growing pipeline of complex biologics and sensitive molecules that require lyophilization creates sustained demand.
The launch of its GMP clinical manufacturing suite opens the high-value early-phase clinical supply market.
Expansion of diagnostic partnerships, fueled by its lyobead generator technology, presents another growth vector.

Risk Factors

Competition from larger, full-service CDMOs and economic pressures on client R&D budgets pose market risks.
Operational execution risk is tied to the successful launch of the new GMP suite and retention of key technical experts.
The company's niche focus, while a strength, also limits its addressable market compared to broad-service CDMOs.

Competitive Landscape

Biopharma Group competes in the specialized segment of the CDMO market focused on lyophilization. Competitors include other niche lyo-specialist firms, the formulation development units of large CDMOs (e.g., Lonza, Catalent), and in-house capabilities at large pharma. Its differentiation lies in its deep, consultancy-level expertise, proprietary lyobead technology, and integrated offering from R&D to clinical supply.

More companies in United Kingdom →